Enanta Pharmaceuticals (ENTA) reported Monday positive topline results from a phase 2 study evaluating zelicapavir in children with respiratory syncytial virus.
The company said zelicapavir showed a significant antiviral effect in young children with respiratory syncytial virus and that the experimental drug reduced viral loads in both hospitalized and non-hospitalized infants compared to placebo.
The drug was also well-tolerated and had a favorable safety profile, Enata added.
Shares of the company were down 2.6% in recent trading.
Price: 7.79, Change: -0.21, Percent Change: -2.63
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。